The circumsporozoite protein (CSP) from the surface of sporozoite stage Plasmodium sp. malaria parasites is among the most important of the malaria vaccine candidates. Gene gun injection of genetic vaccines encoding Plasmodium berghei CSP induces a significant protective effect against sporozoite challenge; however, intramuscular injection does not. In the present study we compared the immune responses and protective effects induced by P. berghei CSP genetic vaccines delivered intradermally with a needle or epidermally with a gene gun. Mice were immunized three times at 4-week intervals and challenged by a single infectious mosquito bite. Although 50 times more DNA was administered by needle than by gene gun, the latter method induced significantly greater protection against infection. Intradermal injection of the CSP genetic vaccine induced a strong Th1-type immune response characterized by a dominant CSP-specific immunoglobulin G2a (IgG2a) humoral response and high levels of gamma interferon produced by splenic T cells. Gene gun injection induced a predominantly Th2-type immune response characterized by a high IgG1/IgG2a ratio and significant IgE production. Neither method generated measurable cytotoxic T lymphocyte activity. The results indicate that a gene gun-mediated CS-specific Th2-type response may be best for protecting against malarial sporozoite infection when the route of parasite entry is via mosquito bite.Vaccination by using "naked" plasmid DNA is revolutionizing vaccine development. Genetic vaccines have been employed in animal studies to induce protective immune responses against a variety of viruses, bacteria, and parasites (5), and preliminary Phase I testing has been conducted in humans (30,34).Because genetic vaccination induces a response in both the humoral and cellular arms of the immune system, this approach offers new opportunities in malaria vaccine development. Genetic vaccines encoding the circumsporozoite protein (CSP) gene from Plasmodium yoelii (28) and Plasmodium berghei (17) protected against malaria infection in BALB/c mice. Intramuscular (i.m.) needle injection of the P. yoelii CSP vaccine induced a significant protective effect against an intravenous sporozoite challenge (28). Epidermal (e.d.) injection of the P. berghei CSP vaccine conferred a significant protective effect against a challenge by infectious mosquito, but intramuscular injection did not (17). i.m. immunization with the P. yoelii CSP vaccine initially induced an interleukin 4 (IL-4)-dependent Th2-type response (19) that quickly switched to a Th1-type response characterized by upregulation of gamma interferon (IFN-␥), induction of high titers of immunoglobulin G2a (IgG2a), and cytotoxic leukocyte (CTL) activity after boosting. Epidermal immunization with the P. berghei CSP vaccine resulted in a much slower progression from a Th2-type response toward a Th1-type response, which was measured by IgG1-toIgG2a isotype switching (17). Although CTLs specific to the known H-2K d class I epitopes of P. berghei were not de...